BrainCool (STO:BRAIN) Third Quarter 2024 Results
Key Financial Results
- Revenue: kr9.18m (up 93% from 3Q 2023).
- Net loss: kr11.3m (loss widened by 3.8% from 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BrainCool shares are down 2.8% from a week ago.
Risk Analysis
You still need to take note of risks, for example - BrainCool has 5 warning signs (and 2 which make us uncomfortable) we think you should know about.
Valuation is complex, but we're here to simplify it.
Discover if BrainCool might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:BRAIN
BrainCool
A medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden.
Moderate with adequate balance sheet.
Similar Companies
Market Insights
Community Narratives
